News
NEW YORK (MarketWatch) -- Shares of CV Therapeutics fell more than 4% in pre-open trading after Deutsche Bank downgraded the Palo Alto, Calif. biopharmaceutical company to sell from hold, on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback